Related Experiment Videos
Azulfidine therapy for ulcerative colitis in infancy
Southern Medical Journal
|April 1, 1979
Insights
This case study highlights a young infant with extensive ulcerative colitis who responded well to salicylazosulfapyridine. This suggests medical therapy is a valuable first step before considering steroids or surgery.
Area of Science:
- Pediatric Gastroenterology
- Inflammatory Bowel Disease Research
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Extensive colonic disease in infants is rare and challenging to manage.
- Standard treatment often involves steroids or colectomy for severe cases.
Observation:
- A pediatric patient presented with extensive colonic disease at an unusually young age.
- The patient exhibited a significant positive response to salicylazosulfapyridine therapy.
- This response occurred despite the extensive nature of the disease and the patient's young age.
Findings:
- Salicylazosulfapyridine (SASP) demonstrated efficacy in treating severe ulcerative colitis in an infant.
- The patient's condition improved significantly with SASP, indicating a favorable response to medical management.
- The case provides evidence for the effectiveness of SASP in a challenging pediatric UC scenario.
Implications:
- This case underscores the potential benefit of initiating medical therapy with salicylazosulfapyridine for infants diagnosed with ulcerative colitis.
- It suggests that SASP may be a viable alternative to steroids or colectomy as a first-line treatment in select pediatric cases.
- Further research into SASP's role in early-onset pediatric UC is warranted.
Abstract:
The reported patient represents an example of extensive colonic disease at an uncommon age of involvement. The significant response to salicylazosulfapyridine therapy with this degree of involvement at this age is uncommon. This case suggests the value of an initial trial of medical therapy with salicylazosulfapyridine before the use of steroids or colectomy is contemplated in infants with ulcerative colitis.